GlassScriptPhysician profile
Jacob R Nelson
NPI 1942591664
$3,765.26
in general payments reported to CMS, 2019-2025
37 companies · $3,565 in 2025
The $3,565 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.80 · 2020: $12.92 · 2022: $13.98 · 2023: $17.93 · 2024: $144 · 2025: $3,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,725 · Education: $2.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,724.74 |
| Education | $2.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $611.20 | 2024-2025 | Dupixent |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $403.73 | 2025 | Caplyta |
| Pfizer INC. | $243.36 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $216.11 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $212.29 | 2025 | Nucala, Shingrix, Arexvy |
| Amgen INC. | $195.36 | 2024-2025 | Repatha, Otezla, Tezspire |
| Novo Nordisk INC | $175.97 | 2025 | Wegovy, Rybelsus, Ozempic |
| Antares Pharma, INC. | $167.73 | 2025 | Xyosted |
| Boston Scientific Corporation | $166.22 | 2025 | Intracept |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.90 | 2024-2025 | Jardiance |
| Genzyme Corporation | $92.67 | 2025 | |
| Axsome Therapeutics, INC. | $90.54 | 2025 | Auvelity, Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $89.86 | 2025 | Trintellix |
| Abbott Laboratories | $83.51 | 2025 | Freestyle Libre 3 |
| Gilead Sciences, INC. | $78.05 | 2022-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $75.29 | 2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $70.54 | 2024-2025 | |
| Radius Health, INC. | $63.91 | 2025 | Tymlos |
| Madrigal Pharmaceuticals | $51.98 | 2025 | Rezdiffra |
| Viatris Specialty LLC | $51.93 | 2025 | Yupelri |
| Lundbeck LLC | $50.99 | 2025 | Rexulti |
| Almatica Pharma LLC | $48.59 | 2025 | Teriparatide, Loreev Xr |
| Janssen Biotech, INC. | $47.79 | 2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $43.49 | 2025 | |
| Phathom Pharmaceuticals, INC. | $40.78 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.86 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $31.35 | 2025 | Gardasil 9, Capvaxive |
| Edwards Lifesciences Corporation | $30.64 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $30.32 | 2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $24.85 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $24.83 | 2025 | Fasenra |
| Orthofix Medical, INC. | $23.72 | 2019-2020 | |
| Esperion Therapeutics, INC. | $21.79 | 2025 | Nexletol |
| Seqirus USA INC | $20.12 | 2025 | Fluad, Flucelvax |
| Paratek Pharmaceuticals, INC. | $19.26 | 2025 | Nuzyra |
| Exact Sciences Corporation | $15.84 | 2025 | The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $14.89 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.